Finance

Lists
Q2 2027 earnings • in 5 days
See details
RDY:NYSE
Dr Reddy's Laboratories Ltd
13,07 USD
+1,32%
(+0,17) 1D
13,07 USD
0,00% (0,00)
After hours
Closed: 16-окт., 16:00:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
13,00 USD
High
13,07 USD
Low
12,94 USD
Mkt. cap
10,81 млд
Avg. vol.
3,19 млн
Volume
2,79 млн
Dividend
0,64%
Quarterly dividend
0,02 USD
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
31,34
52-wk high
15,67 USD
52-wk low
11,36 USD
EPS
0,42 USD
Beta
0,30
Shares outstanding
834,64 млн
No. of employees
28 миң
Open
13,00 USD
High
13,07 USD
Low
12,94 USD
Mkt. cap
10,81 млд
Avg. vol.
3,19 млн
Volume
2,79 млн
Dividend
0,64%
Quarterly dividend
0,02 USD
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
31,34
52-wk high
15,67 USD
52-wk low
11,36 USD
EPS
0,42 USD
Beta
0,30
Shares outstanding
834,64 млн
No. of employees
28 миң
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 миң
Founded1984
HeadquartersHyderabad, Эндра Прадеш, Индия
SectorPharmaceutical industry
Analyst ratings
Based on 2 analysts giving stock ratings to RDY in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RDY in the last 3 months.
Highest
Current 13,07 USD
14,80 USD (+13,24%)
Average
14,80 USD (+13,24%)
Lowest
14,80 USD (+13,24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tausif Shaikh
Exane BNP Paribas
Buy
Upgraded
14,80 USD
+13,2%
10/12/2026
Neha Manpuria
Bank of America Securities
Buy
Maintained
-
-
10/01/2026
Unknown Analyst
Citi
Sell
Maintained
-
-
04/23/2026
Next call 5 күндөн кийин
23-окт., жума, 16:00
Fiscal period
Q2 2027
- / 8,95 INR
Revenue / Est. (INR)
- / 85,94 млд
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
88,05 млд
87,27 млд
75,16 млд
80,70 млд
Cost of goods sold
39,91 млд
40,46 млд
41,47 млд
43,16 млд
Cost of revenue
39,91 млд
40,46 млд
41,47 млд
43,16 млд
Research and development expenses
6,20 млд
6,15 млд
5,46 млд
5,77 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,44 млд
26,92 млд
27,76 млд
28,82 млд
Operating expense
31,90 млд
32,48 млд
32,53 млд
34,11 млд
Total operating expenses
71,81 млд
72,94 млд
74,00 млд
77,27 млд
Operating income
16,24 млд
14,33 млд
1,16 млд
3,43 млд
Other non operating income
1,28 млд
570,00 млн
512,00 млн
-
EBT including unusual items
18,35 млд
15,43 млд
1,99 млд
5,53 млд
EBT excluding unusual items
17,81 млд
15,52 млд
1,82 млд
4,09 млд
Income tax expense
4,08 млд
3,53 млд
-214,00 млн
1,18 млд
Effective tax rate
22,24%
22,90%
-10,75%
21,32%
Other operating expenses
-740,00 млн
-591,00 млн
-693,00 млн
-477,00 млн
Net income
14,37 млд
12,10 млд
2,20 млд
4,44 млд
Net profit margin
16,32%
13,86%
2,93%
5,50%
Earnings per share
17,87
14,77
5,74
5,33
Interest and investment income
912,00 млн
796,00 млн
890,00 млн
999,00 млн
Interest expense
-907,00 млн
-944,00 млн
-1,06 млд
-1,26 млд
Net interest expenses
5,00 млн
-148,00 млн
-167,00 млн
-256,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
21,29 млд
19,54 млд
5,03 млд
8,80 млд
Gain or loss from assets sale
-308,00 млн
-179,00 млн
-2,10 млд
-368,00 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору